Enzo Therapeutics, a biopharmaceutical subsidiary of Enzo Biochem (ENZ:NYSE), designs and develops enabling platforms based on immune and genetic regulation. These platforms offer multiple approaches for the treatment of a variety of diseases. The Company has focused its efforts in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, and cancer. Many of the promising therapeutic applications currently under development are derived from pioneering work initiated at Enzo Life Sciences.

Enzo has concentrated its development on treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. Our focused efforts have generated a clinical and preclinical pipeline that is strongly supported by more than 40 patents and patent applications.

Enzo Therapeutics has established mutually rewarding, long-term relationships with academic institutions and enjoys a positive synergy with the Company's other two subsidiaries, Enzo Life Sciences and Enzo Clinical Labs.